Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
303 questions in 64 reviews · Hepato-Biliary
current versionsNo studies 303 · 100%Ungraded 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Intervention NR Interventions · people with cirrhosis and spontaneous bacterial peritonitis Antibiotic treatment for spontaneous bacterial peritonitis in people with decompensated liver cirrhosis: a… (2019) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Liver transplantation · people with cirrhosis and spontaneous bacterial peritonitis Antibiotic treatment for spontaneous bacterial peritonitis in people with decompensated liver cirrhosis: a… (2019) · Cochrane | no estimate extracted | NR | No studies |
Oral vs intravenous acetylcysteine Hepatotoxicity · people with paracetamol (acetaminophen) overdose Interventions for paracetamol (acetaminophen) overdose (2018) · Cochrane | no estimate extracted | NR | No studies |
Oral plus intravenous acetylcysteine vs intravenous acetylcysteine Hepatotoxicity · people with paracetamol (acetaminophen) overdose Interventions for paracetamol (acetaminophen) overdose (2018) · Cochrane | no estimate extracted | NR | No studies |
Glucocorticosteroid avoidance or withdrawal vs glucocorticosteroid‐based immunosuppression Outcomes** · liver transplanted patients Glucocorticosteroid‐free versus glucocorticosteroid‐containing immunosuppression for liver transplanted… (2018) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Health‐related quality of life · infants with biliary atresia Glucocorticosteroids for infants with biliary atresia following Kasai portoenterostomy (2018) · Cochrane | no estimate extracted | NR | No studies |
Intervention vs no intervention or control intervention (control) Hepatocellular carcinoma · people with acute hepatitis C infection Pharmacological interventions for acute hepatitis C infection (2018) · Cochrane | no estimate extracted | NR | No studies |
Intervention vs no intervention or control intervention (control) Health‐related quality of life · people with acute hepatitis C infection Pharmacological interventions for acute hepatitis C infection (2018) · Cochrane | no estimate extracted | NR | No studies |
Intervention vs no intervention or control intervention (control) Liver transplantation · people with acute hepatitis C infection Pharmacological interventions for acute hepatitis C infection (2018) · Cochrane | no estimate extracted | NR | No studies |
Intervention vs no intervention or control intervention (control) Decompensated liver disease · people with acute hepatitis C infection Pharmacological interventions for acute hepatitis C infection (2018) · Cochrane | no estimate extracted | NR | No studies |
Intervention vs no intervention or control intervention (control) Cirrhosis · people with acute hepatitis C infection Pharmacological interventions for acute hepatitis C infection (2018) · Cochrane | no estimate extracted | NR | No studies |
Gemcitabine plus vandetanib vs vandetanib All‐cause mortality at 1 year · people with advanced biliary tract carcinomas Gemcitabine‐based chemotherapy for advanced biliary tract carcinomas (2018) · Cochrane | no estimate extracted | NR | No studies |
Gemcitabine vs vandetanib Time to progression of the tumour · people with advanced biliary tract carcinomas Gemcitabine‐based chemotherapy for advanced biliary tract carcinomas (2018) · Cochrane | no estimate extracted | NR | No studies |
Gemcitabine plus cisplatin vs S‐1 plus cisplatin Serious adverse events · people with advanced biliary tract carcinomas Gemcitabine‐based chemotherapy for advanced biliary tract carcinomas (2018) · Cochrane | no estimate extracted | NR | No studies |
Gemcitabine plus cisplatin vs S‐1 plus cisplatin Health‐related quality of life · people with advanced biliary tract carcinomas Gemcitabine‐based chemotherapy for advanced biliary tract carcinomas (2018) · Cochrane | no estimate extracted | NR | No studies |
Gemcitabine plus cisplatin vs S‐1 plus cisplatin Time to progression of the tumour · people with advanced biliary tract carcinomas Gemcitabine‐based chemotherapy for advanced biliary tract carcinomas (2018) · Cochrane | no estimate extracted | NR | No studies |
Gemcitabine plus S‐1 vs S‐1 Health‐related quality of life · people with advanced biliary tract carcinomas Gemcitabine‐based chemotherapy for advanced biliary tract carcinomas (2018) · Cochrane | no estimate extracted | NR | No studies |
Gemcitabine plus S‐1 vs S‐1 Time to progression of the tumour · people with advanced biliary tract carcinomas Gemcitabine‐based chemotherapy for advanced biliary tract carcinomas (2018) · Cochrane | no estimate extracted | NR | No studies |
Gemcitabine plus oxaliplatin vs best supportive care Serious adverse events · people with advanced biliary tract carcinomas Gemcitabine‐based chemotherapy for advanced biliary tract carcinomas (2018) · Cochrane | no estimate extracted | NR | No studies |
Gemcitabine plus oxaliplatin vs best supportive care Health‐related quality of life · people with advanced biliary tract carcinomas Gemcitabine‐based chemotherapy for advanced biliary tract carcinomas (2018) · Cochrane | no estimate extracted | NR | No studies |
Gemcitabine plus oxaliplatin vs best supportive care Time to progression of the tumour · people with advanced biliary tract carcinomas Gemcitabine‐based chemotherapy for advanced biliary tract carcinomas (2018) · Cochrane | no estimate extracted | NR | No studies |
Gemcitabine plus vandetanib vs vandetanib Health‐related quality of life · people with advanced biliary tract carcinomas Gemcitabine‐based chemotherapy for advanced biliary tract carcinomas (2018) · Cochrane | no estimate extracted | NR | No studies |
Gemcitabine plus oxaliplatin vs 5‐fluorouracil plus folinic acid Serious adverse events · people with advanced biliary tract carcinomas Gemcitabine‐based chemotherapy for advanced biliary tract carcinomas (2018) · Cochrane | no estimate extracted | NR | No studies |
Gemcitabine plus oxaliplatin vs 5‐fluorouracil plus folinic acid Helath‐related quality of life · people with advanced biliary tract carcinomas Gemcitabine‐based chemotherapy for advanced biliary tract carcinomas (2018) · Cochrane | no estimate extracted | NR | No studies |
Gemcitabine plus oxaliplatin vs 5‐fluorouracil plus folinic acid Time to progression of the tumour · people with advanced biliary tract carcinomas Gemcitabine‐based chemotherapy for advanced biliary tract carcinomas (2018) · Cochrane | no estimate extracted | NR | No studies |
Gemcitabine plus oxaliplatin vs 5‐fluorouracil plus cisplatin plus radiotherapy Health‐related quality of life · people with advanced biliary tract carcinomas Gemcitabine‐based chemotherapy for advanced biliary tract carcinomas (2018) · Cochrane | no estimate extracted | NR | No studies |
Gemcitabine plus oxaliplatin vs 5‐fluorouracil plus cisplatin plus radiotherapy Overall response rate · people with advanced biliary tract carcinomas Gemcitabine‐based chemotherapy for advanced biliary tract carcinomas (2018) · Cochrane | no estimate extracted | NR | No studies |
Gemcitabine plus oxaliplatin vs 5‐fluorouracil plus cisplatin plus radiotherapy Time to progression of the tumour · people with advanced biliary tract carcinomas Gemcitabine‐based chemotherapy for advanced biliary tract carcinomas (2018) · Cochrane | no estimate extracted | NR | No studies |
Gemcitabine plus mitomycin C vs capecitabine plus mitomycin C Serious adverse events · people with advanced biliary tract carcinomas Gemcitabine‐based chemotherapy for advanced biliary tract carcinomas (2018) · Cochrane | no estimate extracted | NR | No studies |
Gemcitabine plus mitomycin C vs capecitabine plus mitomycin C Health‐related quality of life · people with advanced biliary tract carcinomas Gemcitabine‐based chemotherapy for advanced biliary tract carcinomas (2018) · Cochrane | no estimate extracted | NR | No studies |
Gemcitabine plus mitomycin C vs capecitabine plus mitomycin C Time to progression of the tumour · people with advanced biliary tract carcinomas Gemcitabine‐based chemotherapy for advanced biliary tract carcinomas (2018) · Cochrane | no estimate extracted | NR | No studies |
Gemcitabine plus vandetanib vs vandetanib Time to progression of the tumour · people with advanced biliary tract carcinomas Gemcitabine‐based chemotherapy for advanced biliary tract carcinomas (2018) · Cochrane | no estimate extracted | NR | No studies |
Gemcitabine vs vandetanib All‐cause mortality at 1 year · people with advanced biliary tract carcinomas Gemcitabine‐based chemotherapy for advanced biliary tract carcinomas (2018) · Cochrane | no estimate extracted | NR | No studies |
Gemcitabine vs vandetanib Helath‐related quality of life · people with advanced biliary tract carcinomas Gemcitabine‐based chemotherapy for advanced biliary tract carcinomas (2018) · Cochrane | no estimate extracted | NR | No studies |
L‐ornithine L‐aspartate vs probiotic Quality of life assessed using questionnaires · people with cirrhosis who had minimal or overt hepatic encephalopathy or who were at risk for developing hepatic… L‐ornithine L‐aspartate for prevention and treatment of hepatic encephalopathy in people with cirrhosis (2018) · Cochrane | no estimate extracted | NR | No studies |
L‐ornithine L‐aspartate vs probiotic Non‐serious adverse events assessed using ICH‐GCP · people with cirrhosis who had minimal or overt hepatic encephalopathy or who were at risk for developing hepatic… L‐ornithine L‐aspartate for prevention and treatment of hepatic encephalopathy in people with cirrhosis (2018) · Cochrane | no estimate extracted | NR | No studies |
L‐ornithine L‐aspartate vs rifaximin Quality of life assessed using questionnaires · people with cirrhosis who had minimal or overt hepatic encephalopathy or who were at risk for developing hepatic… L‐ornithine L‐aspartate for prevention and treatment of hepatic encephalopathy in people with cirrhosis (2018) · Cochrane | no estimate extracted | NR | No studies |
L‐ornithine L‐aspartate vs lactulose Quality of life assessed using questionnaires · people with cirrhosis who had minimal or overt hepatic encephalopathy or who were at risk for developing hepatic… L‐ornithine L‐aspartate for prevention and treatment of hepatic encephalopathy in people with cirrhosis (2018) · Cochrane | no estimate extracted | NR | No studies |
External beam radiotherapy (EBRT) vs transarterial chemoembolisation (TACE) Elevated alanine aminotransferase · people with unresectable hepatocellular carcinoma External beam radiotherapy for unresectable hepatocellular carcinoma (2017) · Cochrane | no estimate extracted | NR | No studies |
External beam radiotherapy (EBRT) vs transarterial chemoembolisation (TACE) Elevated total bilirubin · people with unresectable hepatocellular carcinoma External beam radiotherapy for unresectable hepatocellular carcinoma (2017) · Cochrane | no estimate extracted | NR | No studies |
External beam radiotherapy (EBRT) plus transarterial chemoembolisation (TACE) vs TACE alone Health‐related quality of life · people with unresectable hepatocellular carcinoma External beam radiotherapy for unresectable hepatocellular carcinoma (2017) · Cochrane | no estimate extracted | NR | No studies |
External beam radiotherapy (EBRT) plus transarterial chemoembolisation (TACE) vs TACE alone Serious adverse events · people with unresectable hepatocellular carcinoma External beam radiotherapy for unresectable hepatocellular carcinoma (2017) · Cochrane | no estimate extracted | NR | No studies |
External beam radiotherapy (EBRT) vs transarterial chemoembolisation (TACE) Serious adverse events · people with unresectable hepatocellular carcinoma External beam radiotherapy for unresectable hepatocellular carcinoma (2017) · Cochrane | no estimate extracted | NR | No studies |
Ursodeoxycholic acid vs placebo Cholecystectomy · people with primary sclerosing cholangitis Pharmacological interventions for primary sclerosing cholangitis (2017) · Cochrane | no estimate extracted | NR | No studies |
Ursodeoxycholic acid vs placebo Serious adverse events · people with primary sclerosing cholangitis Pharmacological interventions for primary sclerosing cholangitis (2017) · Cochrane | no estimate extracted | NR | No studies |
Ursodeoxycholic acid vs placebo Number of adverse events · people with primary sclerosing cholangitis Pharmacological interventions for primary sclerosing cholangitis (2017) · Cochrane | no estimate extracted | NR | No studies |
Ursodeoxycholic acid vs placebo Any malignancy · people with primary sclerosing cholangitis Pharmacological interventions for primary sclerosing cholangitis (2017) · Cochrane | no estimate extracted | NR | No studies |
Ursodeoxycholic acid vs placebo Colorectal cancer · people with primary sclerosing cholangitis Pharmacological interventions for primary sclerosing cholangitis (2017) · Cochrane | no estimate extracted | NR | No studies |
Nutrition support vs no intervention, placebo, or treatment All‐cause mortality · hospitalised adults at nutritional risk Nutrition support in hospitalised adults at nutritional risk (2017) · Cochrane | no estimate extracted | NR | No studies |
Nutrition support vs no intervention, placebo, or treatment Serious adverse events · hospitalised adults at nutritional risk Nutrition support in hospitalised adults at nutritional risk (2017) · Cochrane | no estimate extracted | NR | No studies |